98%
921
2 minutes
20
Our organization, Black in Immuno (@BlackInImmuno), was formed in September 2020 to celebrate, support, and amplify Black voices in immunology when social media campaigns like #BlackInTheIvory illuminated the shared overt and covert issues of systemic racism faced by Black researchers in all facets of science, technology, engineering, art, and mathematics. Black in Immuno was cofounded by a group of Black immunology trainees working at multiple institutions globally: Joël Babdor, E. Evonne Jean, Elaine Kouame, Alexis S. Mobley, Justine C. Noel, and Madina Wane. We devised Black in Immuno Week, held November 22-28, 2020, as a global celebration of Black immunologists. The week was designed to advocate for increased diversity and accessibility in immunology, amplify Black excellence in immunology, and create a community of Black immunologists who can support each other to flourish despite barriers in academia and other job sectors. The week contained live panels and scientific talks, a casual networking mixer, online advocacy and amplification sessions, and a series of wellness events. Our live-streamed programs reached over 300 individuals, and thousands of people kept the conversations going globally using #BlackInImmuno and #BlackInImmunoWeek on social media from five continents. Below, we highlight the events and significant takeaways of the week.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.4049/jimmunol.2100667 | DOI Listing |
Animals (Basel)
July 2025
Facultad de Medicina, Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe, 28660 Boadilla del Monte, Spain.
Host genetic variability is relevant to understanding how parasites modulate natural selection in wild fish populations. Coastal lagoons are transitional ecosystems where knowledge lacks on relationships between genotypic diversity with parasitism. The aim of this study was to assess the effect of genetic diversity on host health and parasitological traits in fish inhabiting a Mediterranean lagoon.
View Article and Find Full Text PDFOncologist
July 2025
Division of Pathology Oncology, University of Texas Southwestern Medical Center, Dallas, TX.
Background: Our objective is to compare the response rate between two matched cohorts of early-stage TNBC (chemotherapy: CT + immune checkpoint inhibitor: ICI vs. CT alone) and to define clinicopathological variables to identify a subgroup of patients who could be spared or benefit from ICI.
Methods: Patients treated with CT + ICI according to KEYNOTE-522 (KN-522) (n = 128) were included in the study and matched 1:1 with patients treated with CT alone.
Cancer Res Commun
August 2025
University of Florida Health Cancer Center, Gainesville, Florida.
Unlabelled: A disparity persists in advanced-stage laryngeal cancer outcomes, in which Black patients experience lower survival rates. We examined real-world treatment patterns and outcomes by race and ethnicity in patients with advanced-stage laryngeal cancer in Florida. Data were abstracted from the Florida Cancer Data System on non-Hispanic (NH)-White, Hispanic, and NH-Black patients with advanced-stage laryngeal cancer from 2009 to 2020.
View Article and Find Full Text PDFCancer Cell
July 2025
Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, UK; Department of Medical Oncology, University College London Hospitals, Lo
Cancers rarely respond completely to immunotherapy. While tumors consist of multiple genetically distinct clones, whether this affects the potential for immune escape remains unclear due to an inability to isolate and propagate individual subclones from human cancers. Here, we leverage the multi-region TRACERx lung cancer evolution study to generate a patient-derived organoid - T cell co-culture platform that allows the functional analysis of subclonal immune escape at single clone resolution.
View Article and Find Full Text PDFJ Immunother Cancer
May 2025
St John's Institute of Dermatology, School of Basic and Medical Biosciences and KHP Centre for Translational Medicine, Guy's Hospital, King's College London, London, UK
Background: The majority of patients with melanoma develop immune-related adverse events (irAEs), and over half do not respond to anti-PD-1 (Programmed cell death protein 1) checkpoint inhibitor (CPI) immunotherapy. Accurate predictive biomarkers for both response to therapy and development of irAEs are currently lacking in clinical practice. Here, we conduct deep immunophenotyping of circulating regulatory and class-switched B cell and antibody immune states in patients with advanced stage III/IV melanoma prior to and longitudinally during CPI.
View Article and Find Full Text PDF